Systems Engineer (4 - 6 Month Contract) MannKind Corporation. DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic . Danbury, CT. May 11, 2023. The '+' indicates that both terms must be present. ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. Search jobs. . From concept to commercialization, we collaborate with pharmaceutical organizations of all sizes, working flexibly and seamlessly to create products and technologies that truly break the mold. Mr.","language":"en","releaseDate":{"dateUTC":"2020-07-20T13:00:00","date":"2020-07-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/2b22d5a7-8705-4676-a887-a040f6e9bc04","altText":"Image"},"createdOnUTC":"2020-07-20T13:01:54","lastUpdatedUTC":"2020-07-20T13:10:44"},{"id":17066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-june-2020-lytham-partners-virtual"},"title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET ( 9 am","language":"en","releaseDate":{"dateUTC":"2020-06-17T21:00:00","date":"2020-06-17T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-17T21:00:44","lastUpdatedUTC":"2020-06-17T21:00:44"},{"id":17051,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-original-analyses-afrezzar-clinical"},"title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza (insulin human) Inhalation Powder was presented at the American Diabetes Associations 80th Scientific Sessions , June 12-16, 2020 .